About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Press Releases
Our latest news and press releases
All
2024
2023
2022
2021
2020
2019
02
Feb
2023
17:47 E.S.T.
Cellectis Announces Pricing of Follow-On Offering
Read more
02
Feb
2023
16:19 E.S.T.
Cellectis Announces Launch of Follow-On Offering
Read more
20
Jan
2023
16:30 E.S.T.
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
Read more
17
Jan
2023
07:10 E.S.T.
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
Read more
04
Jan
2023
17:00 E.S.T.
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq
Read more
29
Dec
2022
16:30 E.S.T.
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
Read more
28
Dec
2022
12:59 E.S.T.
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
Read more
22
Dec
2022
16:30 E.S.T.
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
Read more
13
Dec
2022
07:30 E.S.T.
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
Read more
01
Dec
2022
16:30 E.S.T.
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
Read more
Prev
5
6
7
8
9
Next